ArticleMolecular biology reports2026
Salidroside alleviates sepsis-associated acute lung injury through modulation of the ERK/FoxO3a signaling axis and improvement of impaired autophagic flux.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSepsis-associated acute lung injury (ALI) is a major cause of mortality, and its underlying molecular mechanisms remain incompletely understood. Impaired autophagic flux is considered an important pathological event in this process. Salidroside (Sal), a natural bioactive compound, exhibits anti-inflammatory and cytoprotective effects; however, its role in sepsis-associated ALI requires further investigation.
methodsNetwork pharmacology and molecular docking were employed to identify potential targets and explore candidate signaling pathways. In vitro and in vivo models of sepsis-associated ALI were established using lipopolysaccharide (LPS)-treated RLE-6TN cells and cecal ligation and puncture (CLP) in rats, respectively. Western blotting, immunofluorescence, Ad-mCherry-GFP-LC3B assay, transmission electron microscopy, and JC-1 staining were performed to assess the ERK/FoxO3a signaling pathway, autophagic flux, and mitochondrial function. Phorbol 12-myristate 13-acetate (PMA), an ERK activator, was used for mechanistic validation.
resultsNetwork pharmacology analysis suggested that the ERK/FoxO3a signaling axis may be involved in the effects of Sal. Experimental results showed that Sal reduced inflammatory responses and attenuated lung injury in both in vitro and in vivo models. Sepsis was associated with impaired autophagic flux, as indicated by increased LC3-II/LC3-I ratio and p62 accumulation, whereas Sal treatment decreased p62 levels and promoted autolysosome formation, suggesting improvement of impaired autophagic flux. In addition, Sal reduced ERK phosphorylation and was associated with increased nuclear localization of FoxO3a. PMA partially attenuated the effects of Sal on ERK/FoxO3a-related changes, autophagy-associated markers, and mitochondrial function.
conclusionsSalidroside exerts protective effects in sepsis-associated ALI, which may be associated with modulation of the ERK/FoxO3a signaling axis, improvement of impaired autophagic flux, and maintenance of mitochondrial function.
Indexed as
Identifiers
42635681What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.